Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2022-09-14 Director's Dealing
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-09-14 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the resignation of a Chief Operating Officer and Chief Commercial Officer, and the promotion of another executive to Chief Operating Officer and Chief Legal Officer. This is a clear announcement of changes in the company's senior management. There are no financial statements or detailed financial data present, so it is not an Annual Report, Interim Report, or Earnings Release. The document fits the category of Board/Management Information (MANG) as it announces changes in the company's board of directors or senior management.
2022-09-08 English
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 30, 2022, by Cidara Therapeutics, Inc. The key content is a notice from Nasdaq regarding the company's failure to meet the $1.00 minimum bid price requirement for continued listing, and the company's intention to request a hearing to avoid delisting. The document is short (3845 characters) and focuses on the delisting notice and related procedural information. This matches the definition of a Delisting Announcement (DLST), which is an official notice that the company's stock will be removed from an exchange or is at risk of removal. There is no financial data or other report content, so it is not an Annual Report, Earnings Release, or similar. Therefore, the correct classification is DLST with high confidence.
2022-09-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 9, 2022. It announces the issuance of a press release reporting financial results for the second quarter ended June 30, 2022. The document itself does not contain the financial results but references the press release as an exhibit. The length is 3709 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, since this document announces the release of a financial report (the press release) and does not contain substantive financial data itself, it should be classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR).
2022-08-09 English
CIDARA THERAPEUTICS, INC. FORM 10-Q
Interim / Quarterly Report Q2 2022
2022-08-09 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content details a License Agreement between Cidara Therapeutics, Inc. and Melinta Therapeutics, Inc., including financial terms, licensing rights, development responsibilities, and commercialization plans. There is no indication that this is a full annual or quarterly report, audit report, earnings release, or other financial statement. Instead, it is an announcement of a material definitive agreement, which is a typical use of Form 8-K Item 1.01. Therefore, the document fits best into the category of Capital/Financing Update (CAP), as it relates to a significant licensing and financial arrangement impacting the company's capital and business operations.
2022-07-27 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.